Pf-06835375 — Competitive Intelligence Brief

Pf-06835375 (pf-06835375) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunotherapy. Area: Oncology.

marketed Immunotherapy PD-L1 Oncology Small molecule

Target snapshot

Pf-06835375 (pf-06835375) — Pfizer.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Pf-06835375 TARGET	pf-06835375	Pfizer	marketed	Immunotherapy	PD-L1
DURVALUMAB	DURVALUMAB		marketed	Programmed Death Ligand-1 Blocker [EPC]	PD-L1	2017-01-01
AVELUMAB	AVELUMAB		marketed	Programmed Death Ligand-1 Blocker [EPC]	PD-L1	2017-01-01
Cisplatin / Carboplatin，Gemcitabine，Cindilimab	Cisplatin / Carboplatin，Gemcitabine，Cindilimab	People's Hospital of Quzhou	marketed	Combination chemotherapy with immune checkpoint inhibitor	DNA (platinum agents, gemcitabine); PD-L1 (cindilimab)
Avelumab first-line maintenance	Avelumab first-line maintenance	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	marketed	PD-L1 inhibitor	PD-L1
AB	AB	GlaxoSmithKline	marketed	PD-L1 inhibitor	PD-L1
PD-1 / PD-L1 monoclonal antibody	PD-1 / PD-L1 monoclonal antibody	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	marketed	PD-1/PD-L1 inhibitor	PD-1 and/or PD-L1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunotherapy class)

1. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
2. Beijing Tiantan Hospital · 1 drug in this class
3. CytoVac A/S · 1 drug in this class
4. Hannover Medical School · 1 drug in this class
5. Pfizer · 1 drug in this class
6. The Cleveland Clinic · 1 drug in this class
7. Zarour, Hassane, MD · 1 drug in this class